REG - IXICO plc - Notice of Results and Investor Presentation

IXICOAnnouncement

25/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241125:nRSY4838Na&default-theme=true

RNS Number : 4838N  IXICO plc  25 November 2024

25 November 2024

 

IXICO plc

("IXICO" or the "Company")

 

 

Notice of Results and Investor Presentation

 

IXICO PLC (AIM: IXI), the global medical imaging analysis company delivering
insights in neuroscience, confirms that it will issue its Full Year
Results for the year to 30 September 2024 on Wednesday 4 December 2024.

Bram Goorden (CEO) and Grant Nash (CFO) will provide a live presentation to
all existing and potential shareholders relating to their Full Year Results
and IXICO's expansion and growth strategy via:

 

The Vox platform on 4 December 2024 at 4.30pm GMT

Questions can be submitted pre-event by sending them to
community@voxmarkets.co.uk up until 9:00am on the day before the meeting.
There will also be an opportunity to ask questions during the presentation.

Investors can sign up here: https://streamyard.com/watch/tuGDjEfcp5K4
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fstreamyard.com%2Fwatch%2FtuGDjEfcp5K4&data=05%7C02%7Cgrant.nash%40ixico.com%7C2707fb639d364117d0c708dd08bff13b%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C638676342688748734%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C4000%7C%7C%7C&sdata=Flcud7cklZCLpsN%2FI1XQBi0UmzgZsDQgXZwDkIwFsgY%3D&reserved=0)
.

 

The Investor Meet Company platform on 5 December 2024 at 4:30pm GMT.

Questions can be submitted pre-event via your Investor Meet
Company dashboard up until 9:00am the day before the meeting or at any time
during the live presentation.

Investors can sign up to Investor Meet Company for free and add to
meet IXICO PLC via:

https://www.investormeetcompany.com/ixico-plc/register-investor
(https://gbr01.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.investormeetcompany.com%2Fixico-plc%2Fregister-investor&data=05%7C01%7Cgrant.nash%40ixico.com%7C48e96739262c40cc6a9a08dbe1db2a52%7Cd5a3b5c97a6b4ab9abee3de97e9d4955%7C0%7C0%7C638352103656193087%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=BEUkgfqKx3cnws7ZeJ3G3pSZ4UtPA7iN7igpV15%2F7f4%3D&reserved=0)

Investors who already follow IXICO PLC on the Investor Meet
Company platform will automatically be invited.

 

 

For further information please contact:

 

 IXICO plc
 Bram Goorden, Chief Executive Officer                 +44 (0)20 3763 7499

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated adviser and sole broker)                       +44 (0)20 7220 0500
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks (Life Sciences Specialist Sales)

 Harriet Ward (Corporate Broking)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

About IXICO | Advanced Analytics | Intelligent Insights.

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORQKQBBCBDDPDB